Metastatic colorectal cancer: Current state and future directions

Journal of Clinical Oncology

Volumn 33, Issue 16, 2015, Pages 1809-1824

  Fakih, Marwan G ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN; VEMURAFENIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; RAS PROTEIN; TUMOR MARKER;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CPG ISLAND; INTENTION TO TREAT ANALYSIS; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MONOTHERAPY; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; WNT SIGNALING PATHWAY; ADVERSE EFFECTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETIC SCREENING; GENETICS; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; RISK FACTOR; TIME; TREATMENT OUTCOME; TRENDS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84937143954     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7633     Document Type: Review

References (75)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
3. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
4. Cassidy J, Clarke S, Díaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012, 2008
5. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676, 2007
6. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
7. Stathopoulos GP, Batziou C, Trafalis D, et al: Treatment of colorectal cancer with and without bevacizumab: A phase III study. Oncology 78:376-381, 2010
8. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
9. Passardi A, Scarpi E, Cavanna L, et al: Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial. J Clin Oncol 31, 2013 (suppl 15s; abstr 3517)
10. Cunningham D, Lang I, Marcuello E, et al: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. Lancet Oncol 14:1077-1085, 2013
11. Tebbutt NC, Wilson K, Gebski VJ, et al: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28:3191-3198, 2010
12. Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
13. Loupakis F, Cremolini C, Masi G, et al: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609-1618, 2014
14. Koopman M, Simkens LH, Ten Tije AJ, et al: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31, 2013 (suppl 15s; abstr 3502)
15. Koopman M, Simkens L, May A, et al: Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl 3s; abstr LBA388)
16. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
17. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
18. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
19. Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 26:689-690, 2008
20. Arnold D, Graeven U, Lerchenmuller CA, et al: Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). J Clin Oncol 32:, 2014 (suppl 5s; abstr 3503∧)
21. Koeberle D, Betticher DC, Von Moos R, et al: Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06). J Clin Oncol 31, 2013 (suppl 15s; abstr 3503)
22. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
23. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
24. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
25. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
26. Price TJ, Peeters M, Kim TW, et al: Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15:569-579, 2014
27. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
28. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713, 2010
29. Seymour MT, Brown SR, Middleton G, et al: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracilresistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. Lancet Oncol 14:749-759, 2013
30. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
31. Tveit KM, Guren T, Glimelius B, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 30:1755-1762, 2012
32. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
33. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
34. Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319, 2008
35. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
36. Tejpar S, Celik I, Schlichting M, et al: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570-3577, 2012
37. Peeters M, Douillard JY, Van Cutsem E, et al: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31:759-765, 2013
38. Heinemann V, von Weikersthal LF, Decker T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 15:1065-1075, 2014
39. Schwartzberg LS, Rivera F, Karthaus M, et al: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240-2247, 2014
40. Venook AP, Niedzwiecki D, Lenz HJ, et al: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wildtype (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32, 2014 (suppl 5s; abstr LBA3)
41. Stintzing S, Modest DP, Fischer von Weikersthal L, et al: Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. Ann Oncol 25:1-41, 2014 (abstr LBA11)
42. Lenz H, Niedzwiecki D, Innocenti F, et al: CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol 25:1-41, 2014 (abstr 5010)
43. Venook A, Niedzwiecki D, Lenz H, et al: CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy. Ann Oncol 25:1-41, 2014 (abstr LBA10)
44. Tol J, Nagtegaal ID, Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99, 2009
45. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
46. Peeters M, Oliner KS, Price TJ, et al: Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl 5s; abstr 3568)
47. Loupakis F, Cremolini C, Salvatore L, et al: FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50:57-63, 2014
48. Laurent-Puig P, Pekin D, Normand C, et al: Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res [epub ahead of print on September 23, 2014]
49. Heinemann V, Modest DP, Fischer von Weikersthal L, et al: Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 32, 2014 (suppl 5s; abstr 3600)
50. Lee MS, Overman MJ, Maru DM, et al: Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti- EGFR monoclonal antibody therapy in metastatic colorectal cancer. J Clin Oncol 32, 2014 (suppl 5s; abstr 3633)
51. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
52. Manceau G, Imbeaud S, Thiébaut R, et al: Hsa-miR-31-3p expression is linked to progressionfree survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 20:3338-3347, 2014
53. Stahler A, Heinemann V, Giessen CA, et al: Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutations on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). J Clin Oncol 32, 2014 (suppl 5s; abstr 3522)
54. Adams RA, Fisher D, Farragher S, et al: Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC). J Clin Oncol 30:207s, 2012 (suppl; abstr 3516)
55. Laurent-Puig P, Bridgewater J, Primrose J, et al: MiR-31-3p is a predictive biomarker of cetuximab effects in a post-hoc analysis in the new EPOC study. Ann Oncol 25:iv167-iv209, 2014 (abstr 543P)
56. Fakih M: Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: The path to more personalized medicine. Future Oncol 9:551-560, 2013
57. Misale S, Di Nicolantonio F, Sartore-Bianchi A, et al: Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Discov 4:1269-1280, 2014
58. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:269s, 2010 (suppl; abstr 3534)
59. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103, 2012
60. Corcoran RB, Ebi H, Turke AB, et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227-235, 2012
61. Hong DS, Morris VK, Fu S, et al: Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 32, 2014 (suppl 5s; abstr 3516)
62. Corcoran RB, Atreya CE, Falchook GS, et al: Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. J Clin Oncol 32, 2014 (suppl 5s; abstr 3517)
63. Bettegowda C, Sausen M, Leary RJ, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24, 2014
64. Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536, 2012
65. Diaz LA Jr, Williams RT, Wu J, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-540, 2012
66. Misale S, Arena S, Lamba S, et al: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 6:224ra26, 2014
67. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
68. Gatalica Z, Snyder C, Maney T, et al: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 23:2965-2970, 2014
69. Lipson EJ, Sharfman WH, Drake CG, et al: Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19:462-468, 2013
70. Bertotti A, Migliardi G, Galimi F, et al: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1:508-523, 2011
71. Aisner DL, Nguyen TT, Paskulin DD, et al: ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 12:111-118, 2014
72. Zeng ZS, Weiser MR, Kuntz E, et al: C-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 265:258-269, 2008
73. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
74. Loupakis F, Cremolini C, Lonardi S, et al: Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol 32, 2014 (suppl 5s; abstr 3519)
75. Troiani T, Napolitano S, Vitagliano D, et al: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res 20: 3775-3786, 2014